Eurofarma gets commercial rights to Summit's ridinilazole
Summit Therapeutics PLC licensed Eurofarma Laboratorios SA exclusive rights to commercialize its antibiotic ridinilazole for Clostridium difficile infection (CDI) in Argentina, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Suriname, Dominican Republic, Uruguay and Venezuela.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.